By Bruce Japsen | Abbott
Laboratories said it has signed a deal with India-based Zydus Cadila of
India to sell a portfolio of the India company’s drugs, including
generic medicines, in 15 emerging markets.

Financial terms of the licensing and supply agreement were not disclosed. Seperately, Abbott said it creating a stand-alone “Established Products Division” that is designed to tap into emerging markets. The new business will be led by 20-year Abbott veteran Michael Warmuth, who most recently has been head of the North Chicago-medical product giant’s diagnostics business. 

Abbott said pharmaceutical sales in emerging markets are growing three times the rate of developed countries.